Abdulaziz Alsaedi

Background/Objectives: Early and accurate quantification of Human Immunodeficiency Virus type 1 (HIV-1) viral load is essential for monitoring antiretroviral therapy and guiding clinical management. Although conventional real-time polymerase chain reaction (PCR) platforms provide reliable viral load measurement, they often require centralized laboratories and longer turnaround times. Cartridge-based systems such as the GeneXpert HIV-1 Viral Load assay offer a simplified testing workflow and may facilitate decentralized molecular testing. This study aimed to evaluate the qualitative and quantitative agreement between the GeneXpert HIV-1 Viral Load assay and the Abbott Alinity m HIV-1 assay. Methods: A total of 102 residual clinical Ethylenediaminetetraacetic acid (EDTA) plasma specimens were analyzed using both the GeneXpert HIV-1 Viral Load assay and the Abbott Alinity m HIV-1 assay. Qualitative agreement was evaluated using positive percent agreement (PPA), negative percent agreement (NPA), overall agreement, and Cohen’s κ coefficient. Quantitative agreement among specimens with paired quantifiable viral load results was assessed using Pearson’s correlation and Bland–Altman analyses. Results: Overall qualitative agreement between the two assays was 95.1%, with a PPA of 92.6%, an NPA of 100.0%, and a Cohen’s κ coefficient of 0.894, indicating almost perfect agreement. Among the 57 specimens with paired quantifiable viral load results, a very strong positive correlation was observed (Pearson’s r = 0.9972; 95% CI: 0.9952–0.9984; p < 0.001). Bland–Altman analysis demonstrated a minimal mean bias of −0.018 log₁₀ IU/mL, with 95% limits of agreement ranging from −0.175 to 0.139 log₁₀ International Units per milliliter (IU/mL). All paired quantitative differences were within the clinically accepted agreement threshold of ±0.5 log₁₀ IU/mL. Conclusions: The GeneXpert HIV-1 Viral Load assay demonstrated excellent qualitative and quantitative agreement with the Abbott Alinity m HIV-1 assay. These findings support the potential use of the GeneXpert HIV-1 Viral Load assay as an alternative testing platform for routine HIV-1 viral load monitoring in appropriate clinical settings.

Background: Monkeypox (MP) is an emerging disease with the capacity for worldwide dissemination, endangering all nations. Healthcare workers (HCWs) frequently act as the initial point of contact for MP patients; therefore, evaluating their understanding of the disease and their perspectives on MP immunisation is crucial for effective prevention and control. This study aimed to assess HCWs’ knowledge of and attitudes toward MP and associated vaccines. Methods: A cross-sectional study was performed, focusing on HCWs in Makkah, Saudi Arabia. Data were collected through a standardised, self-administered online questionnaire provided in both English and Arabic. The questionnaire gathered the participants’ sociodemographic information and assessed their knowledge, opinions, and attitudes concerning MP infection and vaccination. The questionnaire included multiple-choice items with response possibilities such as “Yes”, “No” and “Don’t know”. Results: In total, 428 HCWs participated in this study; 60.7% had adequate knowledge of MP, while 39.3% had inadequate knowledge. Some knowledge of specific aspects of the disease was reported to be variable, with 67.5% correctly identifying MP as a viral infection, 55.1% aware of the endemic nature of the disease in parts of Western and Central Africa, and 65.0% recognising skin rash as a common symptom. In terms of attitudes towards MP vaccination, 47.9% had a positive attitude, while 52.1% had a negative attitude. In total, 65.7% of the respondents indicated that vaccination is essential to controlling MP, while only 23.1% (95% CI: 19.1–27.1%) had received vaccination. Furthermore, 57.0% reported concerns about potential adverse effects. Educational level was significantly associated with knowledge of MP (p = 0.001), while job title (p = 0.008) and years of work experience (p = 0.018) were significantly associated with attitudes towards MP vaccination. Age group was significantly associated with MP vaccination status (p = 0.002), while gender, educational level, job title, and years of work experience were not significantly associated with vaccination status. Conclusions: HCWs demonstrated an adequate level of knowledge about MP; however, important knowledge gaps and negative attitudes towards MP vaccination remained. Despite recognising the importance of vaccination, vaccine uptake was low. Educational level was associated with knowledge about MP, while job title and years of work experience were associated with attitudes towards MP vaccination, and age group was associated with MP vaccination status. Targeted educational interventions and evidence-based awareness programmes may enhance knowledge, improve preparedness for future MP outbreaks, and decrease vaccine hesitancy among HCWs.

Introduction: Multidrug resistant (MDR) bacteria are one of the most important current threats to public health. Therefore, serious concerns were raised about the effectiveness of traditional antibiotics. Cisplatin, a chemotherapeutic agent that is used mainly in cancer treatment, has recently attracted attention and popularity for its potential antibacterial properties. Our study aim is to evaluate the antibacterial properties of cisplatin against several common MDR and non-MDR Gram-positive strains, including Methicillin-Resistant Staphylococcus aureus (MRSA), Methicillin-Susceptible Staphylococcus aureus (MSSA), Coagulase-Negative Staphylococcus (CoNS), and Vancomycin-Resistant Enterococcus (VRE). Methodology: Cisplatin's Minimum Inhibitory Concentration (MIC) was calculated through standard microdilution methods. Results: Our findings indicated that cisplatin had a minimum inhibitory concentration (MIC) of 256 µg/mL across all tested bacterial strains, reflecting its limited antibacterial efficacy in its currently available formulation. However, although the MIC values were high, this study explored cisplatin’s activity against these bacterial strains which uncovers a potential gap about cisplatin clinical effectiveness and indicates that further enhancement is required. Conclusions: These results confirm that cisplatin antibacterial activity has not been extensively explored against these resistant strains. Cisplatin alone shows limited efficacy based on the relatively high MIC values observed. However, combination therapy with other antibiotics may improve its therapeutic potential. Additionally, novel delivery systems—nanoparticle formulations, for instance—could enhance antibacterial activity while reducing toxicity. Future investigations should evaluate these approaches in more detail.

Klebsiella pneumoniae is a major opportunistic pathogen responsible for a wide range of hospital- and community-acquired infections, including respiratory tract infections, urinary tract infections, meningitis, and liver abscesses. Among its emerging forms, hypervirulent K. pneumoniae (hvKp) has gained global attention due to its heightened virulence and ability to cause severe infections in healthy individuals. hvKp differs from classical K. pneumoniae (cKp) in its clinical presentation, often causing metastatic infections, liver abscesses without biliary disease, and multiple-site involvement. Despite initial antibiotic susceptibility, the recent convergence of hvKp virulence traits with antimicrobial resistance genes—especially those conferring multidrug resistance (MDR) and carbapenem resistance—poses a serious therapeutic challenge. This review highlights the epidemiological and clinical distinctions between hvKp and cKp, emphasizing the limitations of current diagnostic markers like the string test. Furthermore, it explores novel therapeutic strategies beyond conventional antibiotics, focusing on promising alternatives such as bacteriophage therapy and antimicrobial peptides (AMPs). Several phages, including PSKP16, vB_Kpn_F13, and phage cocktails, have demonstrated potent activity against hvKp strains, including biofilm-forming and carbapenem-resistant isolates. Likewise, AMPs such as Osmin, AA139-nanoformulations, and scorpion venom-derived Cm38 show efficacy in preclinical models. These emerging approaches hold potential to combat the rising threat of hvKp, especially strains that are extensively drug-resistant. Continued research and investment are essential to translate these findings into clinical practice and ensure effective management of hypervirulent and resistant K. pneumoniae infections.

Pandoraea species are emerging multidrug-resistant pathogens increasingly associated with respiratory tract infections, particularly in cystic fibrosis patients. Despite their growing clinical relevance, these bacteria are underrepresented in the scientific literature. This review aims to consolidate existing evidence regarding Pandoraea species as emerging multidrug-resistant pathogens, with a focus on their taxonomy, diagnostic methodologies, antimicrobial resistance mechanisms, and treatment challenges. By identifying gaps in current therapeutic strategies and the limited clinical outcome data, this review underscores the necessity of advancing research into innovative interventions, such as bacteriophages, antimicrobial peptides, and combination therapies, to enhance patient management and infection control. A comprehensive literature search was conducted using PubMed and Google Scholar, employing relevant keywords to identify case reports, clinical studies, and in vitro research related to Pandoraea infections, resistance mechanisms, and therapeutic strategies. Our findings reveal a significant lack of comprehensive data on therapeutic approaches, particularly concerning bacteriophages, antimicrobial peptides, and combination antibiotic therapies. Furthermore, clinical data on treatment efficacy remain sparse, with the majority of evidence stemming from in vitro studies rather than real-world clinical settings. This review emphasizes the urgent need for further research to address these knowledge deficits and to develop effective therapeutic interventions against Pandoraea infections.